Age (median, IQR) | 67 (55-75) |
Male/female | 33/20 |
SAPS II (median, IQR) | 72 (63-80) |
ICU mortality (n, %) | 20 (38) |
Maximal change in thickness (mean %, 95 % CI) | 32 (27-37) |
Aminoglycoside (AG) use (n, %) | 15 (28) |
Maximal change in thickness in AG subgroup (mean %, SD) | 38 (18) |
Maximal change in thickness in non-AG subgroup (mean %, SD) | 30 (18) |
P | 0.367 |
Corticosteroids (CS) use (n, %) | 26 (49) |
Maximal change in thickness in CS subgroup (mean %, SD) | 34 (17) |
Maximal change in thickness in non-CS subgroup (mean %, SD) | 29 (19) |
P | 0.160 |
Continuous neuromuscular blocking agents administration (n, %) | 14 (28) |
Single dose or more of neuromuscular blocking agents administration (n, %) | 35 (66) |
Sepsis on admission (n, %) | 25 (47) |
Maximal change in thickness in sepsis subgroup (%, SD) | 35 (28-42) |
Sepsis during ICU stay (n, %) | 45 (85) |